Print
Email
Print Edition StoriesThursday, January 15, 2009
Oscient sues Lupin over generic drug
Streaming Video: Mass High Tech All-Stars Thought Leadership Roundtable
In their own words: Tod Woolf, CEO, RXi Pharmaceuticals Corp.
Live from BIO 2008: Josh Boger, president and CEO, Vertex Pharmaceuticals Inc.
A unit of Waltham drug maker Oscient Pharmaceuticals Corp. and its licensing partner have filed a patent infringement case against Maryland firm Lupin Pharmaceuticals Inc. over the cardiovascular drug Antara.
Oscient (Nasdaq: OSCI) subsidiary Guardian II Acquisition Corp. and its licensor, French firm Ethypharm SA, filed the lawsuit in the United States District Court for the District of Maryland against Lupin and its Mumbai-based parent Lupin Limited. According to Oscient officials, Lupin plans to market a generic version of Antara before the patent in question expires in August 2020.
Lupin filed an Abbreviated New Drug Application (ANDA) for the generic drug with the U.S. Food and Drug Administration. Final FDA approval of the generic drug product will be stayed until the earlier of 30 months from Dec. 3, 2008, the date Oscient received notice of Lupin’s application, or a court decision in the lawsuit.
Oscient develops pharmaceutical drugs for the treatment of high blood cholesterol and high triglycerides, as well as treatment for chronic bronchitis and pneumonia. For 2007, the company reported a net loss of $29.8 million on total revenue of $80 million.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
